MERS vaccine
Pre-clinical- Indications
- Middle East Respiratory Syndrome (MERS)
Company intelligence / Profile preview
Brighton Biotech, Inc.
New York, New York, United Statesbrightonbiotech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Brighton Biotech is developing products for unmet medical needs, with their lead candidate NACA in preclinical stage for traumatic brain injuries.
- Therapeutic areas
- Neurology
- Modalities
- small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Augment Pharmaceuticals, Inc.Pharmaceutical Regulatory Services, Inc.PRS Clinical, Inc.
Beyond the preview
Go deeper on Brighton Biotech, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brighton Biotech, Inc..